Columbia Laboratories has a rich heritage in pharmaceutical research and development that has helped place the company on the forefront of women's healthcare and drug delivery. Our products use the principles of bioadhesion to achieve controlled, sustained delivery of hormones and other compounds th…
Columbia Laboratories has a rich heritage in pharmaceutical research and development that has helped place the company on the forefront of women's healthcare and drug delivery. Our products use the principles of bioadhesion to achieve controlled, sustained delivery of hormones and other compounds that are difficult to administer.
Commercially available products using our drug delivery technologies include:
Columbia's products have been commercialized through partnerships, and by our own sales force from 2002 until July 2010 when we sold our progesterone assets to Watson Pharmaceuticals. We are now a focused drug development company that enjoys ongoing royalties from our marketing partners.
In December 2010, we reported positive top-line results from the PREGNANT study, a large, global Phase III clinical trial evaluating PROCHIEVE® 8% (progesterone gel) for the reduction in the risk of preterm birth in women with a short cervix at mid-pregnancy. We intend to file an NDA for this potential new indication in the second quarter of 2011.
We continue to explore new applications for our drug delivery systems.
Team (1)
Sectors Columbia Laboratories serves:
Health Care
Life Sciences
Manufacturing
Technology
Join Axial's Private M&A Platform
Columbia Laboratories connects with qualified M&A advisors through the Axial Platform.
Looking for Buyers?
Reach this investor and hundreds more on Axial. No cost to advisors.
